<bill session="116" type="h" number="8190" updated="2020-11-18T08:15:28Z">
  <state datetime="2020-09-08">REFERRED</state>
  <status>
    <introduced datetime="2020-09-08"/>
  </status>
  <introduced datetime="2020-09-08"/>
  <titles>
    <title type="short" as="introduced">Biosimilar Insulin Access Act of 2020</title>
    <title type="short" as="introduced">Biosimilar Insulin Access Act of 2020</title>
    <title type="display">Biosimilar Insulin Access Act of 2020</title>
    <title type="official" as="introduced">To amend the Public Health Service Act to deem any insulin that is determined by the Secretary to be biosimilar to the reference product to be interchangeable with the reference product, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="G000576"/>
  <cosponsors>
    <cosponsor bioguide_id="S001204" joined="2020-11-17"/>
  </cosponsors>
  <actions>
    <action datetime="2020-09-08">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-09-08" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2020-09-16">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR H4487"/>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Blood and blood diseases"/>
    <term name="Competition and antitrust"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Intellectual property"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <committee-reports/>
</bill>
